表紙
市場調查報告書
商品編碼
1066956

全球下一代婦科癌症診斷市場(2020-2031):技術/產品類型/最終用戶/國家

Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and Country Analysis - Analysis and Forecast, 2020-2031

出版日期: | 出版商: BIS Research Inc. | 英文 231 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球下一代婦科癌症診斷市場預計將在 2031 年增長到 56.6 億美元。

本報告調查了下一代婦科癌症診斷的全球市場,定義和概述了市場,分析了對市場增長、法律和監管框架、贖回趨勢和市場規模變化的各種影響因素。它總結了預測、細分按技術/產品類型/適應症/最終用戶/地區、競爭環境、市場份額、主要公司概況等各種類別。

目錄

第一章定義

第二章調查範圍

第三章調查方法

第 4 章市場

  • 分子分析與技術
  • 分子診斷在婦科癌症中的作用
  • 婦科癌症診斷技術和監管裡程碑時間表
  • 婦科腫瘤新分子檢測
  • 目前的市場規模和增長潛力

第5章生物標誌物在婦科癌症中的作用

  • 婦科癌症的預測分子檢測
  • 伴隨診斷 (CDx)

第 6 章 COVID-19:對全球下一代婦科癌症診斷市場的影響

  • 對供應鍊和運營的影響
  • COVID-19 的影響:全球下一代婦科癌症診斷市場
  • 圍繞 COVID-19 的影響評估

第7章市場動態

  • 概覽
  • 影響分析
  • 市場促進因素
  • 市場製約因素
  • 市場機會

第8章工業考慮

  • 概覽
  • 法律要求/框架:美國
  • 法律要求/框架:歐洲
  • 法律要求/框架:亞太地區
  • 兌換場景
  • 融資場景

第 9 章世界下一代婦科癌症診斷市場:技術分析

  • 概覽
  • 聚合□鏈反應
  • NGS
  • 其他

第 10 章世界下一代婦科癌症診斷市場:按產品類型

  • 概覽
  • 服務
  • 產品

第 11 章世界下一代婦科癌症診斷市場:按適應症

  • 概覽
  • 卵巢癌
  • 宮頸癌
  • 子宮癌

第 12 章世界下一代婦科癌症診斷市場:按最終用戶分類

  • 概覽
  • 學術研究
  • 醫院和門診中心
  • 診斷實驗室
  • 其他

第 13 章世界下一代婦科癌症診斷市場:按地區分列

  • 概覽
  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 其他領域

第 14 章競爭形勢/公司概況

  • 競爭形勢
  • 法律和監管活動
  • 協同活動
  • 併購
  • 產品發布
  • 業務拓展
  • 市場份額分析:按服務提供商
  • 市場份額分析:按產品製造商
  • 增長份額分析:按公司分類

第 15 章公司簡介

  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • BGI Genomics
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • QIAGEN N.V
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.

初創企業

  • 概覽
  • NgeneBio
  • oncgnostics GmbH
  • Self-screen B.V.
  • Strata Oncology, Inc.
目錄
Product Code: BHP1172SA

“Global Next-Generation Gynecological Cancer Diagnostics Market to Reach $5.66 Billion by 2031.”

Market Report Coverage - Next-Generation Gynecological Cancer Diagnostics

Market Segmentation

  • By Product Type - Products and Services
  • By Technology - Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Others
  • By Indication - Ovarian Cancer, Cervical Cancer, and Uterine Cancer
  • By End User - Hospitals and Ambulatory Centers, Diagnostic Laboratories, Academic and Research Institutes, and Other End Users

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, The Netherlands, and Rest-of-Europe
  • Asia-Pacific - China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific
  • Latin America - Mexico, Brazil, and Rest-of-Latin-America
  • Rest-of-the-World

Market Growth Drivers

  • Subsequent Decline in Next-Generation Sequencing (NGS) Cost
  • Increased Recommendations from Government Organizations and Scientific Societies
  • Increased Awareness and Shift Toward Personalized Medicine

Market Challenges

  • Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
  • Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
  • Reimbursement Challenges Across the Countries

Market Opportunities

  • Increased Market Investments and Government Funded Projects
  • Next-Generation Sequencing (NGS) Acceptance by Emerging Nations

Key Companies Profiled

Agilent Technologies, Inc., ARUP Laboratories, BGI Genomics, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • Which gynecological cancers have been considered in the report?
  • What are the key milestones in the development of next-generation gynecological cancer diagnostics?
  • What is the scope of next-generation gynecological cancer diagnostics in the future?
  • What are the major market drivers, restraints, and opportunities in the global next-generation gynecological cancer diagnostics market?
  • What are the key developmental strategies that are being implemented by the key players to sustain this market?
  • What is the impact of COVID-19 on the next-generation gynecological cancer diagnostics market?
  • What are the guidelines implemented by different government bodies to regulate the approval of next-generation gynecological cancer diagnostics panels and assays?
  • How are next-generation gynecological cancer diagnostics being utilized for the development of personalized medicine?
  • What is the role of biomarkers in next-generation gynecological cancer diagnostics?
  • How will the investments by public and private companies and government organizations affect the global next-generation gynecological cancer diagnostics market?
  • What was the market size of the leading segments and sub-segments of the global next-generation gynecological cancer diagnostics market in 2020?
  • How will the industry evolve during the forecast period 2021-2031?
  • What will be the growth rate of the next-generation gynecological cancer diagnostics market during the forecast period 2021-2031?
  • How will each of the segments of the global next-generation gynecological cancer diagnostics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
  • What is the market size of the next-generation gynecological cancer diagnostics market in different countries of the world?
  • Which region is expected to contribute to the highest sales of the next-generation gynecological cancer diagnostics market?
  • What are the reimbursement scenarios and regulatory structures for the next-generation gynecological cancer diagnostics market in different regions?
  • What are the key strategies incorporated by the players of the global next-generation gynecological cancer diagnostics market to sustain the competition and retain their supremacy?

Market Overview

Ovarian, cervical, and uterine cancer are the most common gynecological malignancies among women worldwide. Cervical cancer is the fourth most frequently occurring cancer in women. It is anticipated that cervical cancer cases will increase from approximately 580,000 in 2018 to 700,000 in 2030, with a rise in the annual number of deaths from 311,000 to 400,000. Gynecological cancers are a result of genomic aberrations controlled by epigenetic factors, acquired and heritable mutations, and transcriptional deviations. A comprehensive understanding of the genomic and molecular framework of gynecologic malignancies is critical in the evolution of potent biomarkers for detection and prevention, molecular profiling, and the development of personalized treatment strategies.

Traditionally, genetic analysis of gynecological malignancies was carried out by analyzing small, single portions of deoxyribonucleic acid (DNA), referred to as Sanger sequencing. Advanced molecular genetic testing, including next-generation sequencing, microarray, polymerase chain reaction, have contributed significantly to deciphering the molecular profile of gynecological cancers in recent years. Advancements in the field of sequencing technologies have supported researchers and clinicians to harness knowledge pertaining to these underlying mutations, which further helped the stakeholders to discover biomarkers for guiding targeted therapeutic decisions.

The purpose of this study is to gain a holistic view of the next-generation gynecological cancer diagnostics market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The study defines the products and services utilized for next-generation gynecological cancer diagnostics to improve prognosis and quality of life among women. Mutation molecular profiling is critical for the identification and characterization of unique mutations to facilitate disease manifestation and progression. Comprehensive profiling of biological samples, particularly blood and tissues, can help researchers and clinicians identify specific biomarkers that signify a particular disease. The study aims at deciphering the potential of next-generation gynecological cancer diagnostics in the field of research and diagnostics and its critical role in bolstering the current genomic era to enable personalized medicine in routine healthcare settings.

The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well. It also aims at answering various aspects of the global next-generation gynecological cancer diagnostics market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Within the research report, the market has been segmented into 'product type,' 'technology,' 'indication,' 'end user,' and 'regions.'. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global next-generation gynecological cancer diagnostics market is currently budding due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering a wide range of next-generation gynecological cancer diagnostics products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria
    • 1.1.1 Inclusions
    • 1.1.2 Exclusions

2 Research Scope

  • 2.1 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Next-Generation Gynecological Cancer Diagnostics Market: Research Methodology
  • 3.2 Data Sources
    • 3.2.1 Primary Data Sources
    • 3.2.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Criteria for Company Profiling

4 Market

  • 4.1 Introduction
  • 4.2 Molecular Profiling and Techniques
  • 4.3 Role of Molecular Diagnostics in Gynecological Cancers
  • 4.4 Diagnostic Technologies and Regulatory Landmarks Timeline in Gynecological Cancers
  • 4.5 Emerging Molecular Testing in Gynecological Cancer
  • 4.6 Current Market Size and Growth Potential, $Million, 2021-2031

5 Role of Biomarkers in Gynecological Cancer

  • 5.1 Introduction
  • 5.2 Predictive Molecular Testing in Gynecological Cancer
  • 5.3 Companion Diagnostics (CDx)

6 COVID-19 Impact on Global Next-Generation Gynecological Cancer Diagnostics Market

  • 6.1 Impact on Supply Chain and Operations
  • 6.2 COVID-19 Impact: Global Next-Generation Gynecological Cancer Diagnostics Market
  • 6.3 Pre- and Post-COVID-19 Impact Assessment

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Market Drivers
    • 7.3.1 Subsequent Decline in Next-Generation Sequencing (NGS) Cost
    • 7.3.2 Increased Recommendations from Government Organizations and Scientific Societies
    • 7.3.3 Increased Awareness and Shift Toward Personalized Medicine
  • 7.4 Market Restraints
    • 7.4.1 Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
    • 7.4.2 Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
    • 7.4.3 Reimbursement Challenges Across the Countries
  • 7.5 Market Opportunities
    • 7.5.1 Increased Market Investments and Government Funded Projects
    • 7.5.2 Next-Generation Sequencing (NGS) Acceptance by Emerging Nations

8 Industry Insights

  • 8.1 Overview
  • 8.2 Legal Requirements and Framework in the U.S.
    • 8.2.1 FDA Regulation
    • 8.2.2 CMS Regulation
  • 8.3 Legal Requirements and Framework in Europe
  • 8.4 Legal Requirements and Framework in Asia-Pacific
    • 8.4.1 China
    • 8.4.2 Japan
  • 8.5 Reimbursement Scenario
  • 8.6 Funding Scenario

9 Market Segmentation

  • 9.1 Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), $Million, 2020-2031
    • 9.1.1 Overview
      • 9.1.1.1 Polymerase Chain Reaction (PCR)
        • 9.1.1.1.1 by Value
        • 9.1.1.1.2 by Volume
      • 9.1.1.2 Next-Generation Sequencing (NGS)
        • 9.1.1.2.1 by Value
        • 9.1.1.2.2 by Volume
        • 9.1.1.2.3 Broad Panels
          • 9.1.1.2.3.1 by Value
          • 9.1.1.2.3.2 by Volume
        • 9.1.1.2.4 Targeted Gene Panels
          • 9.1.1.2.4.1 by Value
          • 9.1.1.2.4.2 by Volume
        • 9.1.1.2.5 Single Gene Panels
          • 9.1.1.2.5.1 by Value
          • 9.1.1.2.5.2 by Volume
      • 9.1.1.3 Other Technologies
        • 9.1.1.3.1 by Value
        • 9.1.1.3.2 by Volume

10 Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), $Million, 2020-2031

  • 10.1 Overview
  • 10.2 Services
  • 10.3 Products

11 Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), $Million, 2020-2031

  • 11.1 Overview
  • 11.2 Ovarian Cancer
  • 11.3 Cervical Cancer
  • 11.4 Uterine Cancer

12 Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), $Million, 2020-2031

  • 12.1 Overview
  • 12.2 Academic and Research Institutes
  • 12.3 Hospitals and Ambulatory Centers
  • 12.4 Diagnostic Laboratories
  • 12.5 Other End Users

13 Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031

  • 13.1 Overview
  • 13.2 North America
    • 13.2.1 U.S.
    • 13.2.2 Canada
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 U.K.
    • 13.3.3 France
    • 13.3.4 Italy
    • 13.3.5 Spain
    • 13.3.6 Netherlands
    • 13.3.7 Rest-of-Europe
  • 13.4 Asia-Pacific
    • 13.4.1 China
    • 13.4.2 Japan
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 South Korea
    • 13.4.6 Rest-of-Asia-Pacific
  • 13.5 Latin America
    • 13.5.1 Brazil
    • 13.5.2 Mexico
    • 13.5.3 Rest-of-Latin America
  • 13.6 Rest-of-the-World (RoW)

14 Competitive Landscape and Company Profiles

  • 14.1 Competitive Landscape
  • 14.2 Regulatory and Legal Activities
  • 14.3 Synergistic Activities
  • 14.4 Mergers and Acquisitions
  • 14.5 Product Launches
  • 14.6 Business Expansions
  • 14.7 Market Share Analysis, by Service Providers, 2020
  • 14.8 Market Share Analysis, by Product Manufacturers, 2020
  • 14.9 Growth Share Analysis, by Company, 2019-2020
    • 14.9.1 Growth Share Analysis, by Service Providers, 2019-2020
    • 14.9.2 Growth Share Analysis, by Product Manufacturers, 2019-2020

15 Company Profiles

  • 15.1 Overview
  • 15.2 Agilent Technologies, Inc.
    • 15.2.1 Company Overview
    • 15.2.2 Role of Agilent Technologies, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.2.3 Key Customers of the Company
    • 15.2.4 Key Competitors of the Company
    • 15.2.5 Financials
    • 15.2.6 Key Insights About Financial Health of the Company
    • 15.2.7 Business Strategies
    • 15.2.8 SWOT Analysis
  • 15.3 ARUP Laboratories
    • 15.3.1 Company Overview
    • 15.3.2 Role of ARUP Laboratories in the Global Next-generation gynecological Cancer Diagnostics Market
    • 15.3.3 Key Customers of the Company
    • 15.3.4 Key Competitors of the Company
    • 15.3.5 SWOT Analysis
  • 15.4 BGI Genomics
    • 15.4.1 Company Overview
    • 15.4.2 Role of BGI Genomics in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.4.3 Key Customers of the Company
    • 15.4.4 Key Competitors of the Company
    • 15.4.5 Business Strategies
    • 15.4.6 SWOT Analysis
  • 15.5 CENTOGENE N.V.
    • 15.5.1 Company Overview
    • 15.5.2 Role of CENTOGENE N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.5.3 Key Customers of the Company
    • 15.5.4 Key Competitors of the Company
    • 15.5.5 Financials
    • 15.5.6 Key Insights About Financial Health of the Company
    • 15.5.7 SWOT Analysis
  • 15.6 F. Hoffmann-La Roche Ltd
    • 15.6.1 Company Overview
    • 15.6.2 Role of F. Hoffmann-La Roche Ltd in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.6.3 Key Customers of the Company
    • 15.6.4 Key Competitors of the Company
    • 15.6.5 Financials
    • 15.6.6 Key Insights About Financial Health of the Company
    • 15.6.7 Business Strategies
    • 15.6.8 SWOT Analysis
  • 15.7 Fulgent Genetics, Inc.
    • 15.7.1 Company Overview
    • 15.7.2 Key Customers of the Company
    • 15.7.3 Key Competitors of the Company
    • 15.7.4 Financials
    • 15.7.5 Key Insights About Financial Health of the Company
    • 15.7.6 Business Strategies
    • 15.7.7 SWOT Analysis
  • 15.8 Illumina, Inc.
    • 15.8.1 Company Overview
    • 15.8.2 Role of Illumina, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.8.3 Key Customers of the Company
    • 15.8.4 Key Competitors of the Company
    • 15.8.5 Financials
    • 15.8.6 Key Insights About Financial Health of the Company
    • 15.8.7 SWOT Analysis
  • 15.9 Invitae Corporation
    • 15.9.1 Company Overview
    • 15.9.2 Role of Invitae Corporation in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.9.3 Key Customers of the Company
    • 15.9.4 Key Competitors of the Company
    • 15.9.5 Financials
    • 15.9.6 Key Insights About Financial Health of the Company
    • 15.9.7 Business Strategies
    • 15.9.8 SWOT Analysis
  • 15.1 Konica Minolta, Inc.
    • 15.10.1 Company Overview
    • 15.10.2 Role of Konica Minolta, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.10.3 Key Customers of the Company
    • 15.10.4 Key Competitors of the Company
    • 15.10.5 Financials
    • 15.10.6 Key Insights About Financial Health of the Company
    • 15.10.7 Business Strategies
    • 15.10.8 SWOT Analysis
  • 15.11 Laboratory Corporation of America Holdings
    • 15.11.1 Company Overview
    • 15.11.2 Role of Laboratory Corporation of America Holdings in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.11.3 Key Customers of the Company
    • 15.11.4 Key Competitors of the Company
    • 15.11.5 Financials
    • 15.11.6 Business Strategies
    • 15.11.7 SWOT Analysis
  • 15.12 Myriad Genetics, Inc.
    • 15.12.1 Company Overview
    • 15.12.2 Role of Myriad Genetics, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.12.3 Key Customers of the Company
    • 15.12.4 Key Competitors of the Company
    • 15.12.5 Financials
    • 15.12.6 SWOT Analysis
  • 15.13 OPKO Health, Inc.
    • 15.13.1 Company Overview
    • 15.13.2 Role of OPKO Health, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.13.3 Key Customers of the Company
    • 15.13.4 Key Competitors of the Company
    • 15.13.5 Financials
    • 15.13.6 Key Insights About Financial Health of the Company
    • 15.13.7 SWOT Analysis
  • 15.14 QIAGEN N.V
    • 15.14.1 Company Overview
    • 15.14.2 Role of QIAGEN N.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.14.3 Key Customers of the Company
    • 15.14.4 Key Competitors of the Company
    • 15.14.5 Financials
    • 15.14.6 Key Insights About Financial Health of the Company
    • 15.14.7 Business Strategies
    • 15.14.8 SWOT Analysis
  • 15.15 Quest Diagnostics Incorporated
    • 15.15.1 Company Overview
    • 15.15.2 Role of Quest Diagnostics Incorporated in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.15.3 Key Customers of the Company
    • 15.15.4 Key Competitors of the Company
    • 15.15.5 Financials
    • 15.15.6 SWOT Analysis
  • 15.16 Thermo Fisher Scientific Inc.
    • 15.16.1 Company Overview
    • 15.16.2 Role of Thermo Fisher Scientific Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market
    • 15.16.3 Key Customers of the Company
    • 15.16.4 Key Competitors of the Company
    • 15.16.5 Financials
    • 15.16.6 Key Insights About Financial Health of the Company
    • 15.16.7 SWOT Analysis

Emerging companies

  • 15.17 Overview
  • 15.18 NgeneBio
    • 15.18.1 Company Overview
    • 15.18.2 Role of NgeneBio in the Global Next-Generation Gynecological Cancer Diagnostics Market
  • 15.19 oncgnostics GmbH
    • 15.19.1 Company Overview
    • 15.19.2 Role of oncgnostics GmbH in the Global Next-Generation Gynecological Cancer Diagnostics Market
  • 15.2 Self-screen B.V.
    • 15.20.1 Company Overview
    • 15.20.2 Role of Self-screen B.V. in the Global Next-Generation Gynecological Cancer Diagnostics Market
  • 15.21 Strata Oncology, Inc.
    • 15.21.1 Company Overview
    • 15.21.2 Role of Strata Oncology, Inc. in the Global Next-Generation Gynecological Cancer Diagnostics Market

List of Figures

  • Figure 1: Impact Analysis of Market Drivers and Opportunities in Global Next-Generation Gynecological Cancer Diagnostics Market
  • Figure 2: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031
  • Figure 3: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031
  • Figure 4: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031
  • Figure 5: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031
  • Figure 6: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
  • Figure 7: Global Next-Generation Gynecological Cancer Diagnostics Market Segmentation
  • Figure 8: Figure: Global Next-Generation Gynecological Cancer Diagnostics Market: Methodology
  • Figure 9: Figure: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 10: Figure: Top-Down Approach (Segment-Wise Analysis)
  • Figure 11: Cervical Cancer, Incidence Cases and New Cases (2008-2018)
  • Figure 12: Ovarian Cancer, Incidence Cases and New Cases (2008-2018)
  • Figure 13: Molecular Diagnostics Evolution Timeline
  • Figure 14: Types of Molecular Diagnostics Technologies
  • Figure 15: Diagnostic Technologies and Regulatory Landmark Timeline
  • Figure 16: Type of Non-Invasive Next Generation Novel Molecular Diagnostics
  • Figure 17: Evolution of Sequencing Technologies
  • Figure 18: Difference Between Polymerase Chain reaction (PCR) Across Three Generation Sequencing
  • Figure 19: Global Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 20: Potential Biomarkers for Gynecological Cancer Detection
  • Figure 21: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx), (1998-2020)
  • Figure 22: Number of Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) Assays by Analytical Platform/Technology
  • Figure 23: Laboratory Setting and Testing Methodologies Being Adopted by the Respondent's Laboratories
  • Figure 24: Types of Molecular Testing for Cancer Performed
  • Figure 25: Global Next-Generation Gynecological Cancer Diagnostics Market: COVID-19 Impact
  • Figure 26: Impact of COVID-19 on Global Next-Generation Gynecological Cancer Diagnostics Market
  • Figure 27: Global Next-Generation Gynecological Cancer Diagnostics, Market Dynamics
  • Figure 28: Impact Analysis of Market Drivers and Opportunities on Global Next-Generation Gynecological Cancer Diagnostics Market
  • Figure 29: Cost per Human Genome (2014-2021)
  • Figure 30: Approved Number of Personalized Medicine (2016-2020)
  • Figure 31: Percentage of Food and Drug Administration (FDA) Approved Personalized Medicines (2015-2020)
  • Figure 32: Next-Generation Sequencing (NGS) for Human Papillomavirus (HPV) Detection and Characterization Process Steps
  • Figure 33: Global Next-Generation Gynecological Cancer Diagnostics Market (by Technology), 2020 and 2031
  • Figure 34: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain Reaction (PCR)), $Million, 2020-2031
  • Figure 35: Global Next-Generation Gynecological Cancer Diagnostics Market (Polymerase Chain Reaction (PCR)), Thousand Units, 2020-2031
  • Figure 36: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), $Million, 2020-2031
  • Figure 37: Global Next-Generation Gynecological Cancer Diagnostics Market (Next-Generation Sequencing (NGS)), Thousand Units, 2020-2031
  • Figure 38: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), $Million, 2020-2031
  • Figure 39: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Broad Panels), Thousand Units, 2020-2031
  • Figure 40: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), $Million, 2020-2031
  • Figure 41: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Targeted Gene Panels), Thousand Units, 2020-2031
  • Figure 42: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), $Million, 2020-2031
  • Figure 43: Global Next-Generation Gynecological Cancer Diagnostics Market (by Next-Generation Sequencing (NGS), Single Gene Panels), Thousand Units, 2020-2031
  • Figure 44: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), $Million, 2020-2031
  • Figure 45: Global Next-Generation Gynecological Cancer Diagnostics Market (Other Technologies), Thousand Units, 2020-2031
  • Figure 46: Global Next-Generation Gynecological Cancer Diagnostics Market (by Product Type), 2020 and 2031
  • Figure 47: Global Next-Generation Gynecological Cancer Diagnostics Market (Services), $Million, 2020-2031
  • Figure 48: Global Next-Generation Gynecological Cancer Diagnostics Market (Products), $Million, 2020-2031
  • Figure 49: Global Next-Generation Gynecological Cancer Diagnostics Market (by Indication), 2020 and 2031
  • Figure 50: Global Next-Generation Gynecological Cancer Diagnostics Market (Ovarian Cancer), $Million, 2020-2031
  • Figure 51: Global Next-Generation Gynecological Cancer Diagnostics Market (Cervical Cancer), $Million, 2020-2031
  • Figure 52: Global Next-Generation Gynecological Cancer Diagnostics Market (Uterine Cancer), $Million, 2020-2031
  • Figure 53: Global Next-Generation Gynecological Cancer Diagnostics Market (by End User), 2020 and 2031
  • Figure 54: Global Next-Generation Gynecological Cancer Diagnostics Market (Academic and Research Institutes), $Million, 2020-2031
  • Figure 55: Global Next-Generation Gynecological Cancer Diagnostics Market (Hospitals and Ambulatory Centers), $Million, 2020-2031
  • Figure 56: Global Next-Generation Gynecological Cancer Diagnostics Market (Diagnostic Laboratories), $Million, 2020-2031
  • Figure 57: Global Next-Generation Gynecological Cancer Diagnostics Market (Other End Users), $Million, 2020-2031
  • Figure 58: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region)
  • Figure 59: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), 2020-2031
  • Figure 60: Global Next-Generation Gynecological Cancer Diagnostics Market (by Region), $Million, 2020-2031
  • Figure 61: North America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 62: North America, Market Dynamics
  • Figure 63: North America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
  • Figure 64: U.S. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 65: Canada Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 66: Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 67: Europe, Market Dynamics
  • Figure 68: Europe Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
  • Figure 69: Germany Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 70: U.K. Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 71: France Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 72: Italy Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 73: Spain Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 74: Netherlands Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 75: Rest-of-Europe Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 76: Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 77: APAC, Market Dynamics
  • Figure 78: APAC Next-Generation Gynecological Market (by Country), 2020-2031
  • Figure 79: China Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 80: Japan Next-Generation Cancer Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 81: India Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 82: Australia Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 83: South Korea Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 84: RoAPAC Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 85: Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 86: Latin America, Market Dynamics
  • Figure 87: Latin America Next-Generation Gynecological Cancer Diagnostics Market (by Country), 2020-2031
  • Figure 88: Brazil Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 89: Mexico Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 90: Rest-of-Latin America Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 91: RoW Next-Generation Gynecological Cancer Diagnostics Market, $Million, 2020-2031
  • Figure 92: Share of Key Developments and Strategies, January 2019-January 2022
  • Figure 93: Share of Regulatory and Legal Activities (by Company), January 2019-January 2022
  • Figure 94: Share of Synergistic Activities (by Company), January 2019-January 2022
  • Figure 95: Share of Mergers and Acquisitions (by Company), January 2019-January 2022
  • Figure 96: Share of Product Launches (by Company), January 2019-January 2022
  • Figure 97: Share of Business Expansions (by Company), January 2019-January 2022
  • Figure 98: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Service Providers), 2020
  • Figure 99: Market Share Analysis for Global Next-Generation Gynecological Cancer Diagnostics Market (by Manufacturers), 2020
  • Figure 100: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Service Providers), 2020
  • Figure 101: Growth Share Analysis for Global next-generation gynecological cancer diagnostics, (by Product Manufacturers), 2020
  • Figure 102: Shares of Key Company Profiles
  • Figure 103: Agilent Technologies, Inc.: Product Portfolio
  • Figure 104: Agilent Technologies, Inc.: Overall Financials/Revenue, $Million, 2019-2021
  • Figure 105: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
  • Figure 106: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
  • Figure 107: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
  • Figure 108: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 109: ARUP Laboratories: Service Portfolio
  • Figure 110: ARUP Laboratories: SWOT Analysis
  • Figure 111: BGI Genomics: Product Portfolio
  • Figure 112: BGI Genomics: SWOT Analysis
  • Figure 113: CENTOGENE N.V.: Service Portfolio
  • Figure 114: CENTOGENE N.V.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 115: CENTOGENE N.V.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 116: CENTOGENE N.V.: Revenue (by Region), $Million, 2018-2020
  • Figure 117: CENTOGENE N.V.: R&D Expenditure, $Million, 2018-2020
  • Figure 118: CENTOGENE N.V.: SWOT Analysis
  • Figure 119: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 120: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2019-2021
  • Figure 121: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2019-2021
  • Figure 122: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2019-2021
  • Figure 123: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2019-2021
  • Figure 124: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 125: Fulgent Genetics, Inc.: Service Portfolio
  • Figure 126: Fulgent Genetics, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 127: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 128: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 129: Fulgent Genetics, Inc.: SWOT Analysis
  • Figure 130: Illumina, Inc.: Product Portfolio
  • Figure 131: Illumina, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 132: Illumina, Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 133: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 134: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 135: Illumina, Inc.: SWOT Analysis
  • Figure 136: Invitae Corporation: Service Portfolio
  • Figure 137: Invitae Corporation: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 138: Invitae Corporation: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 139: Invitae Corporation: Revenue (by Region), $Million, 2018-2020
  • Figure 140: Invitae Corporation: R&D Expenditure, $Million, 2018-2020
  • Figure 141: Invitae Corporation: SWOT Analysis
  • Figure 142: Konica Minolta, Inc.: Service Portfolio
  • Figure 143: Konica Minolta, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 144: Konica Minolta, Inc.: Revenue (by Business Segment), $Million, 2019-2020
  • Figure 145: Konica Minolta, Inc.: Revenue (by Healthcare Business), $Million, 2019-2020
  • Figure 146: Konica Minolta, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 147: Konica Minolta, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 148: Konica Minolta, Inc.: SWOT Analysis
  • Figure 149: Laboratory Corporation of America Holdings: Service Portfolio
  • Figure 150: Laboratory Corporation of America Holdings: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 151: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
  • Figure 152: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
  • Figure 153: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 154: Myriad Genetics, Inc.: Service Portfolio
  • Figure 155: Myriad Genetics, Inc.: Overall Financials/Revenue, 2018-2020
  • Figure 156: Myriad Genetics, Inc.: Revenue (by Business Segment), 2018-2020
  • Figure 157: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 158: OPKO Health, Inc.: Service Portfolio
  • Figure 159: OPKO Health, Inc.: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 160: OPKO Health, Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 161: OPKO Health, Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 162: OPKO Health, Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 163: OPKO Health: SWOT Analysis
  • Figure 164: QIAGEN N.V.: Product Portfolio
  • Figure 165: QIAGEN N.V.: Overall Financials/Revenue, 2019-2021
  • Figure 166: QIAGEN N.V.: Revenue (by Segment), 2019-2021
  • Figure 167: QIAGEN N.V.: Revenue (by Region), 2019-2021
  • Figure 168: QIAGEN N.V.: R&D Expenditure, 2019-2021
  • Figure 169: QIAGEN N.V.: SWOT Analysis
  • Figure 170: Quest Diagnostics Incorporated: Service Portfolio
  • Figure 171: Quest Diagnostics Incorporated: Overall Financials/Revenue, $Million, 2018-2020
  • Figure 172: Quest Diagnostics Incorporated: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 173: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 174: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 175: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
  • Figure 176: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2018-2020
  • Figure 177: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
  • Figure 178: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
  • Figure 179: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 180: NgeneBio: Product Portfolio
  • Figure 181: oncgnostics GmbH: Product Portfolio
  • Figure 182: Self-screen B.V.: Product Portfolio
  • Figure 183: Strata Oncology, Inc.: Product Portfolio

List of Tables

  • Table 1: Risks Associated with the Types of Genes Related to Hereditary Ovarian and Uterine Cancer
  • Table 2: Advantages and Limitations of Short-Read Sequencing and Long-Read Sequencing
  • Table 3: National Comprehensive Cancer Network (NCCN) Recommended Predictive Molecular Testing in Gynecological Cancer
  • Table 4: Food and Drug Administration (FDA) Approved Companion Diagnostics (CDx) for Gynecological Cancers
  • Table 5: Reimbursement Scenario Across Major Countries
  • Table 6: Regulatory Framework and Reimbursement Options of NGS-Based Diagnostics Across Major Countries
  • Table 7: Next-Generation Sequencing Clinical Utility in Gynecological Cancers
  • Table 8: Services Offered by Key Players
  • Table 9: Products Offered by Key Players